SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
  • 2
    Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804-811.
  • 3
    Sulkowski M, Rodriguez-Torres M, Lalezari JP, Fessel WJ, Mounzer K, Shuhart MC, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology 2013;58(suppl 1):313A.
  • 4
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
  • 5
    AASLD, IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/. Last accessed May 10, 2014.
  • 6
    Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:18791888.
  • 7
    Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:18891898.
  • 8
    Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:14831493.
  • 9
    Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-0000/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014;370:19731982.
  • 10
    Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-0000/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med 2014;370:19831992.
  • 11
    Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-0000/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:15941603.
  • 12
    Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-0000/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:16041614.
  • 13
    Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection. Hepatology 2013;58(suppl):1377A.
  • 14
    Lawitz E, Vierling JM, Murillo A, Kugelmas M, Gerstoft J, Winkle P, et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 ± RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study. Hepatology 2013;58(suppl 1):244A.